Metastatic colorectal cancer-past, progress and future

Kathryn Field, Lara Lipton

Abstract
The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common challenge faced by surgeons and physicians. The last decade has seen exciting developments in the management of CRC, with significant improvements in prognosis for patients diagnosed with stage IV disease. Treatment options have expanded from 5-fluorouracil alone to a range of pharmaceutical and interventional therapies, improving survival, and providing a cure in selected cases. Enhanced understanding of the biologic pathways most important in colorectal carcinogenesis has led to a new generation of drugs showing promise in advanced disease. It is hoped that in the near future the treatment paradigm of metastatic CRC will be analogous to that of a chronic illness, rather than a rapidly terminal condition. This overview discusses the epidemiology of advanced CRC and currently available therapeutic options including medical, surgical, ablative and novel modalities in the management of metastatic colorectal cancer.

© 2007 WJG. All rights reserved.

Key words: Colorectal cancer; Metastases; Chemotherapy; Oncology; Biological therapies

INTRODUCTION
In most Western societies, colorectal cancer (CRC) is the second most common cause of cancer-related death. Worldwide, over 500,000 deaths per year are attributable to colorectal cancer. Approximately 35% of patients have stage IV (M1, metastatic) disease at presentation and 20-50% with stage II or III disease will progress to stage IV. With the introduction of new therapies and improved surgical techniques the death rate continues to decline at approximately 1.8% per year. The five-year survival rate for stage IV disease overall, remains approximately 10%.

The common sites of metastasis are liver, peritoneum and lung. Approximately 50% of patients with stage IV disease will develop liver metastases. Rectal cancer metastasizes to the lung as commonly as the liver. Cerebral metastases are uncommon; CRC is responsible for around 5% of brain metastases and generally occurs at a late stage in the disease. Peritoneal carcinomatosis may occur from transmural spread of the primary malignancy or perforation at diagnosis and is associated with a poor prognosis.

DIAGNOSIS
Computerized tomography may be used as part of the diagnostic workup of abdominal symptoms or as part of routine surveillance after curative treatment for stage II and III colorectal cancer. It has been shown that surveillance CT imaging carries a survival benefit in this setting, compared with less intensive follow-up. The 2005 American Society of Clinical Oncology (ASCO) guidelines recommend annual chest and abdominal CT scans for the first 3 years after primary treatment for patients at moderate to high risk of recurrence and for whom surgical excision of metastases with curative intent would be appropriate.

Positron emission tomography (PET) is increasingly utilized when potentially curative resection is under consideration. Combining PET with contrast-enhanced CT, compared with CT alone, increases the likelihood of finding extrahepatic metastases (89% vs 64%), new liver metastases after previous liver resection (100% vs 50%), and recurrences at the site of resection of the primary tumour (93% vs 53%). PET, particularly when used with CT, aids in accurate selection of patients for resection of metastases.

Serum carcino-embryonic antigen (CEA) is a useful biomarker for surveillance after treatment of stage II and III colorectal cancer; however, 20% of colorectal cancers do not express CEA. CEA is most sensitive in detecting hepatic metastases, but is less likely to be elevated with isolated pulmonary metastases. The ASCO 2005 guidelines recommend 3 monthly CEA testing for at least 3 years after diagnosis.
MANAGEMENT OF ISOLATED METASTASES

Curative surgery

The 5-year cure rate after resection of liver metastases without extra-hepatic disease is up to 40%, and even more in some series. Improved surgical techniques and chemotherapy response rates have led to an increased number of patients being considered for resection. It is estimated that at least 20% of persons with liver metastases may be suitable to undergo resection with curative intent. The suitability for resection of liver metastases is related to location of disease as resection must leave adequate viable liver (at least 30%), while avoiding major vascular structures as well as absence of extrahepatic disease, usually determined by CT and PET.

Risk factors for reduced survival following hepatic resection include a liver resection margin < 1 cm and multiple versus single metastatic deposits. As an aid to choosing the most appropriate management plan for patients presenting with liver metastases, a computer program (Oncosurge) has been constructed following a comprehensive literature review of treatment options. This tool will be useful for clinicians to assess resectability of patients with liver metastases, in conjunction with discussions in a multidisciplinary setting including experienced hepatobiliary surgeons.

Isolated pulmonary metastases may be considered for surgical resection in patients fit enough for thoracotomy. While operative mortality is just over 1%, 5-year survival rates are approximately 27%, with up to 36.9% reported by one series for solitary metastasis (19.3% for 2 metastases and 7.7% for > 2). One small study comparing 12 patients who underwent pulmonary resection within 3 mo of hepatic resection, to 9 who did not have the lung metastases resected with a 3 year survival of 60% vs 31%. Although small series, these data suggest that pulmonary metastectomy should be considered even after hepatic resection. In retrospective analyses, elevated pre-operative serum CEA was an adverse predictor of survival after pulmonary metastectomy.

The benefit of administering chemotherapy prior to (neo-adjuvant) or after (adjuvant) metastectomy is not yet fully established. Neoadjuvant chemotherapy may downstage tumours to make surgery feasible and more successful and may also aid in control of micrometastatic disease. There have been large studies demonstrating successful resection after neoadjuvant chemotherapy for 15%-20% of liver metastases previously deemed unresectable. Disease progression during chemotherapy is indicative of a very poor prognosis regardless of resection. Although complete response of metastases on imaging may occur, without surgery recurrence is the rule. Thus, current practice is to administer 2-3 mo of neoadjuvant combination chemotherapy with repeat imaging to assess response, followed by surgery if appropriate. Upcoming Phase III trials of pre- and post-operative FOLFOX4 chemotherapy versus surgery alone, may help to form an evidence base for decisions in this area.

Hepatic arterial infusion chemotherapy (HAI)

HAI relies on the preferential blood supply of metastases from the hepatic artery and the dual blood supply of the liver with the portal vein. Higher drug levels are delivered at the sites of metastatic disease. The most common agent used is the 5FU analogue flouxuridine (FUDR). The most serious side effects are biliary sclerosis or catheter-related complications, both of which can be fatal.

Until recently, trials comparing HAI to systemic chemotherapy for liver metastases had demonstrated improved response rates, but survival benefits were less clear. A recent Phase III trial of 135 patients comparing HAI (FUDR, leucovorin (LV) and dexamethasone) to systemic chemotherapy (5FU and LV) showed a 24.4 mo vs 20 mo ($P = 0.0034$) median overall survival benefit favouring HAI. Time to hepatic progression, conversely, was 7.7 mo vs 14.8 mo favouring systemic chemotherapy ($P = 0.029$). As more efficacious agents (oxaliplatin, irinotecan) are now used in treatment of metastatic CRC, it is unclear as to whether superiority of HAI in such studies would be maintained when using these newer agents as comparators. A Cochrane review of HAI chemotherapy after resection or ablation of liver metastases secondary to CRC, found no significant overall survival advantage for HAI; as such this is not currently a recommended intervention after liver resection.

Radiofrequency ablation (RFA)

RFA uses high frequency alternating current creating ionic agitation and heat, resulting in cell death by coagulation necrosis. Percutaneous, laparoscopic, and open surgical techniques may be employed. Patients who are eligible generally have fewer than five metastases, < 5 cm in diameter and clear of major vessels. One recent study of 135 patients found a median survival of 28.9 mo after RFA for surgically unresectable liver metastases. RFA can be considered for lung metastases, where thoracotomy is not indicated (surgically unresectable or the patient is medically unfit). Multiple lesions can be treated in one procedure. The RAPTURE trial of RFA for lung metastases from a variety of malignancies, presented 2 year follow-up data in 2005. Of 53 patients with CRC, 72% remain cancer free at 2 years. A Phase II study of 55 patients with metastatic CRC undergoing RFA demonstrated a 2-year disease-free survival rate of 57% and median overall survival of 33 mo. The major complication of lung RFA is pneumothorax (up to 43% in one study).

Selective internal radiation therapy (SIRT)

SIR-Spheres® are biocompatible radio-active microspheres containing yttrium-90 which emits beta radiation. This Australian invention delivers up to 40 times more radiation to liver metastases than would be possible using conventional radiotherapy, and has shown benefits in liver metastases from both breast and colorectal cancer as well as primary hepatocellular carcinoma (Figure 1). A hepatic arterial catheter is used to deliver the microspheres, which may be combined with HAI or intravenous
chemotherapy. A Phase III trial of 74 patients comparing HAI plus SIRT to HAI alone found a 44% vs 17.6% partial and complete response rate ($P = 0.01$), with a 15.9 mo vs 9.7 mo time to progression ($P = 0.001$), favouring the combination. This technology appears promising for the future.

**SYSTEMIC CHEMOTHERAPY**

Please refer to Tables 1 and 2 for details of chemotherapy acronyms, regimens and key Phase III trials, which are discussed below.

**5-Fluorouracil and calcium leucovorin**

The anti-metabolite 5-fluorouracil (5FU) was the mainstay of chemotherapy for metastatic colorectal cancer in the latter half of the 20th century. The addition of intravenous calcium leucovorin (folic acid, LV) stabilizes the binding of 5FU to thymidylate synthase, enhancing the inhibition of DNA synthesis. Combination therapy was demonstrated in a meta-analysis of nineteen trials compared with mo for supportive care alone. A Phase III trial of �� patients comparing HAI plus SIRT to HAI alone found a % partial response rate, with a 15. mo time to progression, favouring the combination. This technology appears promising for the future.

Despite numerous documented regimens employing either bolus or infusional 5FU, minimal overall survival advantages have been shown for any one although the response rate and progression free survival appear better with infusional schedules, and one meta-analysis suggested a slight survival advantage for infusional over bolus 5FU (12. vs 11.3 m, $P = 0.04$). The side effect profiles differ; infusions of 5FU cause more diarrhea and hand-foot syndrome (erythema, dryness and cracking of palms and soles) while bolus 5FU carries a higher incidence of haematological toxicity. 5FU/LV is used alone in patients who are intolerant or have contra-indications to more complex regimens.

---

**Table 1** Common chemotherapy regimens for metastatic colorectal cancer

| Regimen | Description | Cycle length |
|---------|-------------|-------------|
| 5FU Mayo | 5-FU 425 mg/m²/d D1-5 LV 20 mg/m² D1-5 | 4 wk |
| 5FU Roswell | 5-FU 500 mg/m²/d weekly × 6 | 8 wk |
| Park | LV 500 mg/m²/d weekly × 6 | 2 wk |
| LVFU2(de Gramont) | LV 200 mg/m² D1 and D2 SFU 600 mg/m² CIVI 22 h D1 and D2 | 8 wk |
| LVSFU2 | LV 500 mg/m² D1 weekly × 6 SFU 2300-2600 mg/m² CIVI 24 h D1 weekly × 6 | 3 wk |
| Capcitabine | 1250 mg/m² BD, D1-14 | 2 wk |
| FOLFOX4 | Oxaliplatin 85 mg/m² D1 LV 200 mg/m² D1 and D2 SFU 400 mg/m² D1 and D2 | 2 wk |
| FOLFOX6 | Oxaliplatin 100 mg/m² D1 LV 400 mg/m² D1 SFU 400 mg/m² D1 SFU 2400-3000 mg/m² CIVI 46 h (D1, D2) | 2 wk |
| bFOL | Oxaliplatin 85 mg/m² D1, D15 LV 20 mg/m² D1, D8, D15 SFU 500 mg/m² D1, D8, D15 | 4 wk |
| FUFOX | Oxaliplatin 85 mg/m² D1, 15, 29; LV 20 mg/m² D1, 8, 15, 22, 29 SFU 500 mg/m² D1, 8, 15, 22, 29 | 8 wk |
| FLOX | Oxaliplatin 85 mg/m² D1 wk 1, 3, 5 SFU 500 mg/m² bolus weekly wk 1-6 LV 500 mg/m² bolus weekly wk 1-6 | 8 wk |
| FOLFIRI | Irinotecan 180 mg/m² D1, LV 200 mg/m² D1 and D2 SFU 400 mg/m² bolus D1 and D2 SFU 600 mg/m² D12h and D1, D2 | 2 wk |
| IFL | Irinotecan 100-125 mg/m² weekly × 4 wk LV 20 mg/m² weekly × 4 wk SFU 400-500 mg/m² bolus weekly × 4 wk | 6 wk |
| XELOX | Oxaliplatin 130 mg/m² D1 Capecitabine 1 g/m² BD D1-14 | 3 wk |
| CAPOX | Capecitabine 1 g/m² BD D1-14 Oxaliplatin 70 mg/m² D1, D8 | 3 wk |
| XELIRI | Irinotecan 200-250 mg/d2 D1-14 Capecitabine 1 g/m² BD D1-14 | 3 wk |
| CAPIRI | Capecitabine 1 g/m² BD D1-14 Irinotecan 100 mg/m² D1, D8 | 3 wk |
| FOLFOXIRI | Irinotecan 125-175 mg/m² D1 Oxaliplatin 85-100 mg/m² D1 LV 200 mg/m² D1 SFU 400 mg/m² bolus D1 SFU 3200 mg/m² CIVI 48 h | 2 wk |

D1: day 1; LV: leucovorin; CIVI: continuous intravenous infusion; BD: twice daily; d: daily.
| Author/trial | n   | Arms                          | RR (%) | TTP (mo) | OS (mo)  |
|-------------|-----|-------------------------------|--------|----------|----------|
| Van Cutsem  | 602 | Capecitabine                  | 18.90  | 5.2      | 13.2     |
|             |     | 5FU/LV Mayo                   | 15.00  | 4.7      | 12.1     |
| De Gramont  | 420 | FOLFOX4                       | 50.70  | 9        | 16.2     |
|             |     | LV5FU2                        | 22.30  | 6.2      | 14.7     |
|             |     | (P NA)                        | (P = 0.65 NS) | (P = 0.33 NS) |
| Hochster    | 147 | FOLFOX                        | 41     | 8.7      | 19.2     |
|             |     | bfOL                          | 20     | 6.9      | 17.9     |
|             |     | CapOx                         | 27     | 5.9      | 17.2     |
|             |     | (P NA)                        | (P NA) | (P = 0.12 NS) |
| Hochster    | 213 | FOLFOX + bevacizumab          | 52     | 9.9      | 26       |
|             |     | bfOL + bevacizumab            | 39     | 8.3      | 20.7     |
|             |     | CapOx + bevacizumab           | 46     | 10.3     | 27       |
|             |     | (P NA)                        | (P NA) | (P NA)   |
| Fuchs       | 430 | FOLFIRI                       | 46.60  | 7.6      | 23.1     |
| BICC-C      |     | mIFL                          | 41.90  | 5.8      | 17.6     |
|             |     | CAPIRI                        | 38     | 5.5      | 18.9     |
|             |     | (P NA)                        | (P NA) | (P = 0.19 NS) |
| Fuchs       | 117 | FOLFIRI + bevacizumab         | 54.40  | 9.9      | NR       |
| BICC-C 2    |     | mIFL + bevacizumab            | 53.30  | 8.3      | 18.7     |
|             |     | (P NA)                        | (P NA) | (P NA)   |
| Salz         | 683 | IFL                           | 39     | 7        | 14.8     |
|             |     | 5FU/LV (Mayo)                 | 21     | 4.3      | 12.6     |
|             |     | (P < 0.001)                   | (P = 0.004) | (P = 0.04) |
| Douillard    | 387 | FOLFIRI                       | 35     | 6.7      | 17.4     |
|             |     | LV5FU2 (AIO)                  | 22     | 4.4      | 14.1     |
|             |     | (P = 0.005)                   | (P < 0.001) | (P = 0.031) |
| Tournigand  | 220 | FOLFIRI ≥ FOLFOX6             | 56     | 8.5      | 21.5     |
| GERCOR       |     | FOLFOX6 ≥ FOLFIRI             | 54     | 8        | 20.6     |
|             |     | (P = NS)                      | (P = 0.26 NS) | (P = 0.99 NS) |
| Goldberg    | 795 | FOLFOX4                       | 45     | 8.7      | 19.5     |
| N9741        |     | IFL                           | 31     | 6.9      | 15       |
|             |     | IROX                          | 35     | 6.5      | 17.4     |
|             |     | (P = 0.002)                   | (P = 0.0014) | (P = 0.0001) |
|             |     | (P = 0.03)                    | (P = 0.001) | (P = 0.09 NS) |
|             |     | (P = 0.60 NS)                 | (P = NS) | (P = 0.28 NS) |
| Ross         | 200 | Mitomycin C + infused 5FU     | 54     | 7.9      | 14       |
|             |     | Infusional 5FU                | 38     | 5.4      | 15       |
|             |     | (P = 0.024)                   | (P = 0.033) | (P = NS)   |
| Souglakos et al | 283 | FOLFIRI                       | 43     | 8.4      | 21.5     |
|             |     | FOLFIRI                       | 33.6   | 6.9      | 19.5     |
|             |     | (P = 0.168 NS)                | (P = 0.17 NS) | (P = 0.337 NS) |
|             |     | (P = 0.0002)                  | (P = 0.0006) | (P = 0.032) |
| Falcone     | 244 | FOLFIRI                       | 66     | 9.8      | 22.6     |
|             |     | FOLFIRI                       | 41     | 6.9      | 16.7     |
|             |     | (P = 0.0002)                  | (P = 0.0006) | (P = 0.032) |
|             |     | (P = 0.0002)                  | (P = 0.0001) | (P = 0.001) |
| Hurwitz     | 813 | IFL + bevacizumab             | 44.8   | 10.6     | 20.3     |
|             |     | IFL                           | 34.8   | 6.2      | 15.6     |
|             |     | (P = 0.004)                   | (P < 0.001) | (P < 0.001) |
| Gianetico    | 822 | FOLFIRI                       | 22     | 7.2      | 12.9     |
| EOCGE 3200   |     | FOLFIRI                       | 9      | 4.8      | 10.8     |
|             |     | (P = 0.0001)                  | (P = 0.0018) |
| Cunningham   | 329 | Bevacizumab                   | Discontinued | 4.1      | 8.6      |
| BOND-1       |     | Cetuximab + irinotecan        | 22.9   | 1.5      | 6.9      |
|             |     | Irinotecan                    | 10.8   | 1.5      | 6.9      |
|             |     | (P = 0.007)                   | (P < 0.001) | (P = 0.48 NS) |
| BOND-2       | 74  | Cetuximab + irinotecan + bevacizumab | 38     | 8.5      | n/a      |
|             |     | Cetuximab + bevacizumab       | 23     | 6.9      | n/a      |
|             |     | Panitumumab                   | Improved PFS | (HR 0.54 P < 0.0001) | (P = NS) |
|             |     | BSC                           |         |          |          |

NS: Not significant; BSC: Best supportive care; NA: Not available. All the BICC-C trial all arms were also randomized to +/- celecoxib, which neither improved efficacy nor toxicity of chemotherapy.
Capcitabine (Xeloda®)
This oral pro-drug is converted to 5FU in three enzymatic steps including thymidine phosphorylase, a tumour-associated angiogenic factor, theoretically resulting in increased concentration at the site of metastases. Capcitabine is at least equivalent in efficacy to bolus 5FU in metastatic colorectal cancer. The toxicity profile is similar to infusional 5FU with diarrhoea and hand-foot syndrome of degree in up to 50%-60% of clinical trial subjects, often requiring a dose reduction. Although many patients prefer to use an oral form of chemotherapy rather than attending hospital for intravenous 5FU-based chemotherapy, compliance must be assured when such therapy is used.

Tegafur is an oral 5FU pro-drug given in combination with uracil (UFT) and oral leucovorin. Phase III data comparing UFT/LV with bolus 5FU/LV in previously untreated metastatic CRC demonstrated equivalent overall survival (12.4 mo vs 13.4 mo, P = 0.630 NS) with less diarrhoea and myelosuppression than bolus 5FU.

Oxaliplatin (El现货in®)
This platinum-based agent works by forming platinum-DNA adducts, thus blocking DNA replication. Although it has minimal single-agent activity, it is synergistic with 5FU in the treatment of metastatic CRC. A large Phase III trial of 420 patients compared FOLFOX4 to LV5FU2 (Table 1) and demonstrated improved response rate (50.7% vs 22.3%, P = 0.0001) and progression-free survival (9.0 mo vs 6.2 mo, P = 0.0003), but overall survival was not statistically significantly different, possibly attributable to patients in the control arm later receiving oxaliplatin, thus obscuring any survival benefit. Newer trials have combined capcitabine with oxaliplatin (CAPOX or XELOX), with phase II data demonstrating a 19.5 mo median overall survival. TREE-1 (Table 2), a small Phase III trial, compared CAPOX and two other regimens combining oxaliplatin with 5FU and found equivalent overall survival (OS) in each arm.

Oxaliplatin’s main toxicity is sensory peripheral neuropathy of two types-an acute, temporary cold related dysesthesia; and a chronic cumulative persistent sensory neuropathy which is dose-limiting and may be irreversible. Up to 90% of patients experience some form of acute neurotoxicity and 10%-15% chronic neuropathy. While most fully recover after a median time of 13 wk, in the MOSAIC study which employed the FOLFOX4 regimen, 29% of patients still had some degree of neurotoxicity 12 mo after cessation of therapy.

Irinotecan (CPT11, Campstas®)
Irinotecan, a camptothecin derivative, inhibits Topoisomerase I, impeding DNA uncoupling causing double-stranded DNA breaks. A Phase III trial of 683 patients compared IFL (Table 1) with single agent irinotecan or bolus 5FU/LV (Mayo regimen). Response rate, progression free survival and median overall survival (14.8 mo vs 12.6 mo, P = 0.04) were all improved with IFL. Another Phase III trial randomized 387 patients to FOLFIRI versus LV5FU2 (Table 1). This trial also demonstrated a higher overall survival (median 17.4 mo vs 14.1 mo, P = 0.031), favouring the irinotecan arm. The combination of capcitabine with irinotecan (CAPIRI or XELIRI) in Phase II studies suggest comparable activity to FOLFIRI with a 16-19 mo median overall survival; however, recent data from a phase III trial found a trend towards superior response rate and overall survival with FOLFIRI over CAPIRI (OS 23.1 mo vs 18.9 mo P = 0.19 NS). The main dose-limiting side effect is diarrhoea, experienced in over 50% of patients in these studies. This was of Grade 3 or 4 severity in 22%-44% of those treated.

Mitomycin C
This antineoplastic antibiotic, isolated from Streptomyces caespitosus, is activated to become an alkylating agent in vivo, cross-linking and inhibiting DNA synthesis and function. It demonstrates single-agent activity in metastatic CRC, but is accompanied by a significant risk of neutropenia and a small risk of haemolytic-uraemic syndrome. A randomised study of 200 patients showed a 54% vs 38% response rate in patients receiving mitomycin C and infusional 5FU, compared with 5FU alone (P = 0.024); overall survival was equivalent. Irinotecan added to mitomycin C, in 41 patients who had progressed on 5FU, showed a median overall survival of 11.9 mo. More recently, a phase II study of 36 patients demonstrated efficacy for mitomycin C and capcitabine in irinotecan-refractory metastatic CRC, with a 15.2% response rate and median overall survival of 9.3 mo.

Targeted therapies
Inhibitors of circulating growth and angiogenic factors, their cell surface receptors, and corresponding intracellular tyrosine kinases are increasingly used combined with or as an alternative to chemotherapy. For metastatic CRC, two agents have entered routine clinical practice: the monoclonal antibodies bevacizumab and cetuximab.

Bevacizumab (Avastin®)
Bevacizumab is a humanised monoclonal antibody targeting vascular endothelial growth factor (VEGF), an angiogenic factor over-expressed in approximately 50% of colorectal cancers. The antibody-bound form of VEGF is unable to bind to its cell surface receptor, preventing activation of an intracellular tyrosine kinase pathway which regulates cell proliferation, angiogenesis, and cell survival. Bevacizumab in combination with chemotherapy, is now regarded as appropriate 1st-line therapy for metastatic CRC. After a preliminary Phase II study suggested that bevacizumab had efficacy in combination with 5FU/LV in metastatic CRC, a Phase III trial with 813 previously untreated patients randomized to IFL +/- bevacizumab further demonstrated activity. A significant overall survival advantage was seen favouring the experimental arm (20.3 mo vs 15.6 mo, P < 0.001). An analysis of 3 trials using 5FU/LV +/- bevacizumab demonstrated a 17.9 mo vs 14.6 mo (P = 0.008) overall survival advantage with the combination compared with 5FU-based treatment alone. In the three arm ECOG 3200 study, FOLFOX4 +/- bevacizumab was compared
with bevacizumab alone in 822 patients with previously treated metastatic CRC. The bevacizumab-alone arm was discontinued due to inferiority at an interim analysis. An overall survival advantage (12.9 mo vs 10.8 mo, P = 0.0024) as well as significant response rates and progression-free survival benefits were seen in the FOLFOX4 plus bevacizumab arm\(^8\). The TREE-2 study (Table 2) added bevacizumab to three different oxaliplatin-containing regimens and found improved response rates and time to progression when added to all three\(^9\). The toxicities of bevacizumab when added to chemotherapy alone include hypertension (22% vs 8.3% overall and 11% vs 2% requiring treatment), bleeding or thrombosis, in particular arterial thrombotic events (CVA, AMI, TIA, angina), were increased (5% vs 2.5%), proteinuria in 26% and gastrointestinal perforation in 1.5% or 6/393\(^9\). VEGF is involved in wound healing, which may explain the last complication.

**Cetuximab (Erbitux\(^\circ\))**

This chimeric monoclonal antibody, targeting the extracellular domain of the epidermal growth factor receptor (EGFR or HER-1), has demonstrated activity in metastatic CRC. Although the EGFR gene is over-expressed or upregulated in 60%-80% of colorectal cancers\(^1\), cetuximab response in CRC appears independent of EGFR expression\(^2\). In a phase II study (128 patients) adding cetuximab to irinotecan after failure of irinotecan alone, a 22.5% response rate was obtained\(^8\). In the BOND-1 study of 329 participants refractory to irinotecan, randomised to cetuximab and irinotecan or cetuximab alone, a significantly higher response rate and median time to progression for the combination was seen, although overall survival was no different\(^1\). The above trials explored the use of cetuximab in previously treated patients. Its role in 1\(^\text{st}\)-line treatment; and also in combination with oxaliplatin-based regimens, is yet to be fully elucidated. The main side effect is an acneiform skin rash in up to 80\%\(^4\); the degree of skin reaction may correlate with response rate\(^3,4\). Diarrhoea is relatively common; and allergic reactions may occur, possibly related to the mouse component of the antibody\(^4\).

**Panitumumab**

This antibody also targets the EGFR, but in contrast to cetuximab, it is derived from the XenoMouse, a transgenic mouse which produces fully humanized antibodies\(^6\). A Phase III trial comparing panitumumab with best supportive care in 463 patients with CRC after progression on irinotecan and oxaliplatin, showed 8% vs 0% partial responses and 28% vs 10% with stable disease. No overall survival benefit has been seen to date\(^7\). Rash of some degree occurs in over 90% of patients, and hypomagnesaemia in 38% of patients in this trial, but allergic reactions appear uncommon.

**Which agent and which combination?**

Decisions as to the best choice of therapy are based on performance status, co-morbidities, and the preferences of the individual. The optimal combination and sequencing of therapeutic agents in the metastatic setting is unknown. A randomized study of FOLFIRI followed by FOLFOX6 at progression, or the reverse sequence, demonstrated equivalent time to first progression (8.5 mo vs 8.0 mo P = 0.26) and median overall survival (21.5 mo vs 20.6 mo, P = 0.99)\(^8\). A Phase III study in 795 persons compared FOLFOX4 with IFL and IROX (irinotecan and oxaliplatin). All outcome measures were better for the FOLFOX regimen with median survival 19.5 mo (vs 15 mo for IFL, P = 0.0001 and 17.4 mo for IROX P = 0.09 NS)\(^9\). Because oxaliplatin was not available commercially in the US at the time, the difference in overall survival may have been accentuated by differential access to second-line treatment for those in the two arms of the trial. Additionally, only the FOLFOX4 arm used infusional 5FU, which may have contributed to its advantage. In fact, phase III data from a study of 360 persons comparing FOLFIRI and FOLFOX (both using infusional 5FU), demonstrated no difference in response rate, time to progression and OS between the two arms\(^9\). A recent Phase III study comparing FOLFOXIRI (Tables 1 and 2) to FOLFIRI in 283 participants demonstrated more toxic side effects but no difference in outcomes with the triple combination\(^9\). A further phase III trial compared FOLFOXIRI with FOLFIRI in 244 persons and found a statistically significant overall survival advantage of 22.6 mo vs 16.7 mo (P = 0.032) for the triplet arm with increased but manageable toxicities\(^9\). In practice, most fit patients will receive a number of therapeutic agents for management of metastatic disease, including 5FU, capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab, as overall survival benefits continue to improve (Figure 2).

**CONCLUSION**

The management of metastatic colorectal cancer in the twenty-first century is becoming increasingly complex, with the development of innovative new therapies and further scope for combinations of active agents. In addition, there have been significant advances in surgical and other
ablative and local techniques, and it seems certain that targeted therapies will become a major component of the management of colorectal cancer. Overall, these gains in the last decade are beginning to impact on survival and quality of life for people affected with this devastating disease, and there is hope that terminal metastatic colorectal cancer may one day become a rarity.

REFERENCES

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30
2. Boyle P, Ferlay J. Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol 2005; 2: 424-425
3. Borner MM. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer—too good to be true? Ann Oncol 1999; 10: 625-626
4. Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, Tebbutt N, Tait D, Hill M, Ross PJ, Oates J. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22: 1420-1429
5. Uskent ND. Survival from the precocious brain metastasis of the colon cancer. Turk J Cancer 2003; 33: 154-157
6. Buellet A, Gambini C, Macchia G, Androlli G. Brain metastasis from colon cancer. Case report showing a clinical and CT unusual appearance. J Neurol Sci 1987; 31: 33-36
7. DeVita VHS, Rosenberg S. Cancer - Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005: 2240
8. Committee. ACNCCGR. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. The Cancer Council Australia and Australian Cancer Network; 2005: 94
9. Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause L, Loprinzi CL, Minsky BD, Pfister DG, Pirretti NJ. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23: 8512-8519
10. Lonneux M, Relfad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002; 29: 915-921
11. Tobaruela E, Enriquez JM, Diez M, Camunas J, Muguerza J, Granell J. Evaluation of serum carcinomembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level. Int J Biol Markers 1997; 12: 18-21
12. Taylor I, Mullee MA, Campbell MJ. Prognostic index for the detection of liver metastases in patients with colorectal cancer. Br J Surg 1990; 77: 499-501
13. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321
14. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut G. A study of prognostic factors for hepatic resection for colorectal cancer. Ann Surg 1997; 173: 467-471
15. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2003; 21: 7125-7134
16. Girard P, Baldeyrou P, Grunenwald D. Lung metastases from colorectal cancer: results of surgery. Presse Med 1995; 24: 1028-1052
17. McAfee MK, Allen MS, Trastek VF, Ihstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-785; discussion 785-786
18. Labow DM, Buell JE, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases—is resection indicated? Cancer 2002; 8: 342-347
19. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, Lasser P, Gayet B, Ruftolle P, Grunenwald D. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996; 14: 2047-2053
20. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425-429
21. Adam R, Vibert E, Pitombo M. Induction chemotherapy and surgery of colorectal liver metastases. Bull Cancer 2006; 93 Suppl 1: S45-S49
22. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 239: 1052-1061; discussion 1061-1064
23. Gruenberger T. Tumor response to pre-operative chemotherapy (CT) with FOLFIRI for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Proceedings of the American Society of Clinical Oncology, 2006 June 2-6; Atlanta, GA, USA. Vol 24 (no.18S), Part I, Abstract 3500, 146s
24. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferra N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
25. Bredis C, Young G. The blood supply of neoplasms in the colon cancer. Turk J Cancer 2005; 8: 53-59
26. Lorenzo M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorouracil and folinic acid in patients with hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-254
27. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery fluorouracil infusion for colorectal liver metastases. Lancet 1994; 344: 1255-1260
28. Rougier P, Laplanche A, Hugui er M, Hay JM, Ollivier JM, Esca t J, Salmon R, Jul ien M, Rouilet Audy JC, Gallot D. Hepatic arterial infusion of fluorouracil in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-1118
29. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403
30. Nelson RL, Freels S. A systematic review of hepatic artery chemotherapy after hepatic resection of colorectal cancer metastatic to the liver. Dis Colon Rectum 2004; 47: 739-745
31. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358-1364
32. Poston GJ. Radiofrequency ablation of colorectal liver metastases: where are we really going? J Clin Oncol 2005; 23: 1342-1344
33. Lenconi R. Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE) Trial: 2-Year Survival Outcomes. Proceedings of the Society of Interventional Radiology 30th Annual Meeting, 2005 April; New Orleans, USA. Abstract #506
34. Yan TD, King J, Glenn D, Steinkie K, Morris DL. Percutaneous radiofrequency ablation of inoperable pulmonary metastases from colorectal cancer. Proceedings of the American Society of Clinical Oncology, 2006 June 2-6; Atlanta, GA, USA. Vol 24
Field K et al. Management of metastatic CRC

(2005; 16: 301-308)

Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Oncologist 1999; 4: 478-487

Van Cutsen E, Dose L, Lumey LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-1726

Hoff PM. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist 2005; 11: 345-352

Douillard JY, Cunningham D, Roth AD, Navarro M, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Chang DZ. Abbruzzese JL. Capecitabine plus oxaliplatin in advanced colorectal cancer. J Clin Oncol 1998; 16: 233-236

Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J. Meyer zum Büschenfelde KH, Knuth A. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial.Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14: 2274-2279

Dencausse Y, Hartung G, Sturm J, Kopp-Schneider A, Gamelin E, Castaing D, Bengstson E, Allain P, Louvet C, Gervais M, Gすることは、metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616

Raymond E, Buquet-Fagot C, Djeloul S, Mester J, Chtibovic E, Allain F, Louvet C, Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876-885

Rothenberg ML, Ozna AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Caray CA, Burger BG, Le Bails N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2050-2059

de Gramont A, Figer A, Seymour M, Hemon M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bails N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947

Cassidy J, Tabernerio J, Twelves C, Brunet R, Butts C, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Cassidy J, Tabernerio J, Twelves C, Brunet R, Butts C, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Cassidy J, Tabernerio J, Twelves C, Brunet R, Butts C, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Cassidy J, Tabernerio J, Twelves C, Brunet R, Butts C, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Chang DZ, Abbruzzese JL. Capecitabine plus oxaliplatin or infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. Clin Ade Hentol Oncol 2005; 3: 400-404

Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 2006; 24 suppl 18: S510

Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33

Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29: 11-20

Hsiang YH, Liu IF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-1726

Sallz LB, Cox JV, Blankie C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351

Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005; 39: 128-135

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernerio J, Hickish T, Topalam C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351

Cassidy J, Tabernerio J, Twelves C, Brunet R, Butts C, Conroy T, Debrad F, Figar A, Grossman J, Sawada N, Schöffski P, Sobera A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Janik P, Iverson T, Carmichael J, Alak M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047

Delord JP, Pierga JY, Dieras V, Berthaud-Cvitovic F, Turpin FL, Lokiec F, Loconn I, Chatelut E, Canal P, Guimbaud R, Ychou M, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, squeeze M, Douglass HO Jr, Herrera L, Russell D, Stablein DM, D’Mello MC, Hsu H, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29: 11-20
66 Fuchs C, Marshall J, Mitchell E, Wierzbiicki R, Ganju V, Jeffery M, Schultz J, Richards D, Wang B, Morrison M. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without cetuximab in metastatic colorectal cancer (BICC-C). Clin Oncol 2006; 24 suppl 18: S5306

67 Haskell C. Cancer Treatment. 5th ed. WB Saunders Co, 2001: 181-182

68 Hartmann JT, Kanz L, Bokemeyer C. Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma. Anticancer Res 2000; 20: 1177-1182

69 Anderson N, Lokich J, Moore C, Bern M, Coco F. A dose escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. Cancer Invest 1999; 17: 586-593

70 Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005; 31: 681-690

71 Ross P, Norman A, Cunningham D, Webb A, Iverson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001

72 Yamada Y, Shirao K, Hyodo I, Arai Y, Denda T, Ambo T, Ohtsu A. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol 2003; 52: 125-130

73 Lim DH, Park YS, Park BK, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Mitomycin-C and capcitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005; 56: 10-14

74 Lee JC, Chung SM, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748-753

75 Mulcahy MF, Benson AB. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005; 5: 997-1005

76 Kabbavinar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Grifing S, Bergsland E. Phase II, randomized phase IIb bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65

77 Kabbavinar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712

78 Giantonio B. High-dose bevacizumab improves survival when combined with FOLFOX in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proceedings of the American Society of Clinical Oncology Annual Meeting 2005 May 13-17; Orlando FL, USA. Vol 23 (Suppl. 165), Abstract 2

79 Porebska I, Harlozińska A, Bojarowski T. Expression of the VEGF receptor.

80 Saltz LB, Meropol NJ, Loehrner PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208

81 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bes flash M, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345

82 Saltz L, Rubin M, Hochster H. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proceedings of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco CA, USA. Vol 20 (3a), Abstract 7

83 Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuntoz G, Rocci L, Gabbia N, Tonini G. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006; 17: 833-841

84 Chong G, Cunningham D. The role of cetuximab in the therapy of previously treated advanced colorectal cancer. Semin Oncol 2005; 32: 555-558

85 Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10: 701-709

86 Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231: 11-23

87 Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the American Association for Cancer Research (AACR); 2006 Apr 1-5; Washington DC, USA. Abstract CP-1. Available from URL http://aacs.org

88 Tournigand C, André T, Achille E, Lledo G, Fuch M, Mery-Mignard D, Quinaux E, Couteau B, Buyse M, Ganiem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFOX4 followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237

89 Goldberg RM, Sargent DJ, Mort LM, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30

90 Colucci G, Gabbia V, Paolo E, Gianlini F, Caruso M, Gabbia N, Carteni G, Agostara B, Pefezzall G, Manzione L, Borsellino N, Misio A, Romito S, Durini E, Cordero D, Di Seri M, Lopez M, Mialcello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Ciacenza M, Valerio MR, Guida T, Leonardi V, Piconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C. Phase III randomized trial of FOLFOXIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico DELL‘Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875

91 Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kalkoriesis S, Tsousis S, Kouroussis Ch, Yamvakas L, Kalokyki A, Samonis G, Movriodis Ch, Georgoulis V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94: 798-805

92 Falcone A, Masi G, Brunetti I. The triplet combination of irinotecan, oxaliplatin and 5FU/LVThe triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nort Obest (G.O.N.O.). Proceedings of the American Society of Clinical Oncology; 2006 June 2-6, Atlanta GA, USA. Vol 24 (suppl 1), Part I, Abstract 3513, 149th

93 O’Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63: 1026-1030

94 O’Connell MJ, Maliard JA, Kahn MJ, MacDonald JS, Haller DG, Mayer RJ, Wleand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250

95 de Gramont A, Louvet C, André T, Tournigand C, Raymond E, Molitor JL, Kruilik M. Modulation of 5-fluorouracil with
folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD). Rev Med Interne 1997; 18 Suppl 4: 372s-378s

96 Ychou M, Duffour J, Pinguet F, Kramar A, Joulia JM, Topart D, Bressolle F. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res 1999; 19: 2229-2235

97 Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-1342

98 Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003; 21: 2703-2707

99 Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUXO) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 2002; 40: 957-964

100 Sørbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003; 42: 827-831

101 Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreucci M, Falcone A. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004; 15: 1766-1772

102 Saltz LB, Lenz HJ, Hochster H. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2005; 23 suppl: S248

S- Editor Ma N  L- Editor Rippe RA  E- Editor Ma WH